About BCH

BCH's Brief History

A Houston, TX based, privately held company, BioCapital Holdings, LLC ("BCH") was formed in September 2016.  

The core science behind BCH is the modification of yeast and bacteria DNA to produce genetic devices that can be fermented to produce compounds that are are sustainable, economically sensible, safe GMO free useful products to benefit mankind.  Everything we produce is GMO free and environmentally safe.  BCH focuses on how to produce the high quality products at the lowest costs possible.

Yeast and bacteria are incredible versatile "factories".  For centuries man has utilized yeast to make bread and beer.  In recent years, thanks to the successful genetic mapping of virtually all known organisms, using synthetic biology, yeast and bacteria are used to make a wide variety of pharmaceutical drugs and everyday consumables such as imitation meats, fuels alternatives, leather and scotch.

While most synthetic biology companies focus on medically -based ingestible pharmaceutical products, BCH intentionally chose a direct path.  While some of BCH's devices do produce compounds that are medical related, the majority produce non-consumable products that enrich the quality of everyday life.  BCH wanted to avoid long FDA trial periods and the other issues of pharmaceutical production.

Inception-to-date BCH has been 100% funded by BCH management.  We have built an extremely diverse portfolio of intellectual property that can be monetized into a wide variety of vertical and horizontal industrial applications.  Approaching our first decade of "survival" we have had zero revenues.  Rather, BCH's focus has been on developing and securing over 25 patents, with many more "in the pipeline".  This has included independent outside laboratory testing of many of our compounds to insure consistently meet our goals,.

2025 is a breakthrough year for BCH.  After years of hearing "so what is it exactly do you make?", "are you sure it works?", "is it safe?" and "can it be produce at scale?"  we have those answers.   In 2022, BCH management made a commitment to internally assemble and construct the upstream and downstream the bio-production equipment  necessary to enable BCH to self-produce its entire library of compounds.  Two millions dollars later (and growing!) we are almost there.  Before the end of 2025, BCH's production capacity will include a 200 liter and two twin 2,500 liter pharmaceutical grade bio-fermenters and the related upstream and downstream production equipment needed to meet our goals,